5,568 Shares in Eli Lilly and Company $LLY Acquired by WNY Asset Management LLC

WNY Asset Management LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,568 shares of the company’s stock, valued at approximately $5,121,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Farther Finance Advisors LLC lifted its stake in Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Iams Wealth Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at $754,000. Amundi increased its holdings in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after buying an additional 454,549 shares in the last quarter. May Hill Capital LLC lifted its position in shares of Eli Lilly and Company by 131.6% during the 4th quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock valued at $3,408,000 after acquiring an additional 1,801 shares during the last quarter. Finally, Caisse Des Depots ET Consignations boosted its stake in shares of Eli Lilly and Company by 17.3% during the 4th quarter. Caisse Des Depots ET Consignations now owns 10,834 shares of the company’s stock worth $11,643,000 after acquiring an additional 1,600 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,149.28 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 40.83, a price-to-earnings-growth ratio of 1.43 and a beta of 0.51. The company has a 50 day simple moving average of $1,152.66 and a 200-day simple moving average of $1,044.16. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the prior year, the business earned $3.34 EPS. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 34.91 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly continues to pull ahead of Novo Nordisk in the rapidly expanding obesity-treatment market, with significantly stronger recent revenue growth and a more favorable outlook. Lilly’s latest reported quarter included 55.5% year-over-year revenue growth, while Novo Nordisk expects an adjusted sales decline. Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed.
• Positive Sentiment: The company is investing another $750 million with Resilience to expand U.S. manufacturing capacity for diabetes and obesity medicines. The project is expected to add at least 400 jobs and supports Lilly’s ability to meet continued demand. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: Completion of a late-stage retatrutide trial provides a potential future catalyst in diabetes, obesity and related cardiovascular indications. Lilly has also begun an early-stage study of eloralintide, adding another candidate to its weight-loss pipeline. Lilly’s Retatrutide Trial Completion Signals Next Wave in Diabetes and Obesity Drugs
• Neutral Sentiment: Analysts are focused on key operating metrics for Lilly’s second-quarter results, including demand, prescription trends and guidance. The company’s prior earnings report substantially exceeded estimates, raising expectations for the upcoming release. Lilly Q2 Earnings on the Horizon
• Negative Sentiment: Weight-loss drug stocks came under pressure as investors digested clinical-trial news and positioned ahead of earnings. Technical selling intensified after Lilly fell below a closely watched support level, despite its stronger long-term fundamentals. Weight Loss Drug Stocks Slump

Wall Street Analyst Weigh In

Several brokerages have recently commented on LLY. UBS Group upped their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a report on Monday, July 13th. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Wolfe Research restated an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, Royal Bank Of Canada upped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.